Title: Innovation in cancer treatment: Using a novel ‘theranostic’ agent to enhance the diagnostic and therapeutic properties of chemotherapy

Duration: 60 minutes including Q&A

This event took place on Thursday, October 08, 2015 and is now available to view on-demand

Register Now

Registration is required to attend this event. Please register now. Please see our privacy policy and use of cookies.

 If you have previously registered for this event, please login below:

First Name*
Last Name*
Address Line 1*
Address Line 2
Zip / Postal Code*
Do you currently own, or have regular access to cell analysis instrumentation, such as a flow cytometer or image-based cell analyzer?*
What area of research are you most interested in?
(Select all that apply.)*
Outsourced Clinical BioAnalytical Services
Outsourced Discovery / Preclinical Services
Lead Discovery (HTS & Lead Optimization)
ADME & Toxicity
Cell Structure - Invasion/Migration
Infectious Disease
Stem Cell Research
Which application techniques/products are you the most interested in?
(Select all that apply.)*
Analytical Sample Prep
Bradford/IR Protein Quantitation
Cell Counting/Viability
Cell Culture
Drug Absorption/Diffusion Evaluations
Drug Safety/Testing
Flow Cytometry & Imaging
Live Cell Analysis
Other assays - ChIP/IHC/IF/ICC
Protein Purif./Concentration/Depletion
RNA Detection
Small Molecules/Inhibitors
Tissue Isolation/Depletion/Enrichment
Western Blotting
By registering for this webcast, your registration details will be shared with Nature Publishing Group and EMD Millipore who may contact you about their respective programs, products or services. We will not otherwise disclose your personal data outside these organisations unless we have your permission as detailed in our Privacy Policy (http://www.nature.com/info/privacy.html) . I agree* 
Please enable Cookies in your browser before registering for the webcast.
*Denotes required.
We will process your data in accordance with privacy policy and use of cookies.

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.

Innovation in cancer treatment: Using a novel ‘theranostic’ agent to enhance the diagnostic and therapeutic properties of chemotherapy

According to the American Cancer Society, there will be more than 1.7 million new cases of cancers diagnosed in 2015. More than 50% of these patients will be treated with DNA damaging agents as part of their therapy.  Unfortunately, many will not respond favorably to these treatments for several reasons that include ineffective DNA repair and the subsequent misreplication of unrepaired DNA lesions.

The Berdis lab has taken an innovative approach to combat the latter complication by developing a series of non-natural nucleoside analogs that selectively and potently inhibit the ability of specialized DNA polymerases to replicate certain DNA lesions.

In this webcast, Dr. Anthony Berdis will discuss a specific nucleoside analog designated 5-Endosine which shows unprecedented specificity for targeting terminal deoxynucleotidyl transferase (TdT) and pol eta, two specialized DNA polymerases involved in replicating DNA lesions in cancers such as acute lymphoblastic leukemia.

He will discuss how 5-Endosine can be used as a “theranostic agent” – compounds that possess both therapeutic and diagnostic activities. Combining these properties provides a way to accurately measure the therapeutic activity of the drug in real time and ultimately represents a new area in personalized medicine that may lead to more effective treatments and patient responses to chemotherapy.

During this webcast, you will learn:

  • How a non-natural nucleoside can reduce unfavorable patient response to DNA-damaging therapy.
  • Why a new diagnostic assay that predicts patient response to chemotherapy may enable the use of individualized cancer therapeutics.
  • How a single-cell analysis tool can rapidly provide quantitative data from cell cycle and apoptosis assays critical to the therapeutic-screening process.

You will also have the opportunity to ask questions of our speaker, live during the broadcast!

Webcast sponsors retain sole responsibility for content.


Dr. Anthony J. Berdis, Cleveland State University

Anthony J. Berdis, Ph.D. is an Associate Professor in the Department of Chemistry and the Center for Gene Regulation in Health and Disease at Cleveland State University. In addition, he is Co-Founder and Chief Scientific Officer of Red5 Pharmaceuticals, LLC.  Dr. Berdis has over 25 years of research experience in diverse biomedical fields including mechanistic enzymology, medicinal chemistry, cancer biology, and cancer chemotherapeutics. Dr. Berdis is an internationally recognized expert in the field of synthesis and biological testing of novel nucleoside and nucleotide analogs as both therapeutic and diagnostic agents to target DNA polymerase activity.

ON24 ON24
ON24 ON24

Moderator: Dr. Jayshan Carpen, Nature Publishing Group

Jayshan received his Ph.D. in neurogenetics from the University of Surrey, UK. His doctoral thesis focused on identifying polymorphisms associated with diurnal preference and circadian sleep disorders. Jayshan worked as an events coordinator at the Royal Institution of Great Britain before moving to his current role in 2013 for Nature Publishing Group (NPG).